RedHill Biopharma Ltd. (RDHL) Fair Value 2026

RDHL · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (50/100)

Quick Summary — As of 2026-08-28, RedHill Biopharma Ltd. (RDHL) trades at $0.66. QOC: 4.1/10. Value Trap Risk: 50/100 (WARN). 1/13 models active.

Key Facts

Ticker
RDHL
Price
$0.66
Quality Score
4.1/10
Value Trap Risk
50/100
Models Active
1/13
Last Updated
Strength: Regime Cross-Sectional suggests +314.6% upside with 17% confidence
Risk: Value Trap score of 50 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give RDHL?

1 Intrinsic Value Models vs. Current Price ($0.66)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $2.74 +314.6%

All Models Active

All 1 models are displayed above.

What Is RedHill Biopharma Ltd. (RDHL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, RedHill Biopharma Ltd.'s intrinsic value is estimated at a median fair value of $2.74. At a current market price of $0.66, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +314.6%.

What Do the Models Say About RDHL?

1 of 13 models are currently active for RDHL. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does RDHL Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, RDHL ranks #100 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to healthcare company businesses. For RedHill Biopharma Ltd., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is RDHL a Value Trap?

CirclFi's Value Trap algorithm assigns RDHL a score of 50/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for RedHill Biopharma Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, RedHill Biopharma Ltd. scores 4.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RDHL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RDHL's 1 active models, average confidence is 17%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy RedHill Biopharma Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

PTPIPetros Pharmaceuticals, Inc.QOC 4.1KAYSKaya Holdings, Inc.QOC 3.9GRPSGold River Productions, Inc.QOC 4.1SHPHShuttle Pharmaceuticals Holdings, Inc.QOC 3.6BUDZWEED, Inc.QOC 4.2NIKANIKA PHARMACEUTICALS INC.QOC 3.5PBHPrestige Consumer Healthcare Inc.QOC 8.3CPIXCumberland Pharmaceuticals Inc.QOC 6.3CGCCanopy Growth CorporationQOC 5.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: PTPI · KAYS · GRPS · SHPH · BUDZ · NIKA · PBH · CPIX · CGC · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to RDHL?

7 companies across all industries closest to RDHL’s Quality of Company score of 4.1/10.

BLIVBeLive HoldingsQOC 4.1PTNPalatin Technologies, Inc.QOC 4.1PFSAProfusa, Inc.QOC 4.1PDSBPDS Biotechnology CorporationQOC 4.1NGENNervGen Pharma Corp.QOC 4.1SOBRSOBR Safe, Inc.QOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BLIV · PTN · PFSA · PDSB · NGEN · SOBR · NVDA

Where Does RDHL Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

RDHL is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About RedHill Biopharma Ltd.’s Valuation?

What is RedHill Biopharma Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for RedHill Biopharma Ltd. (RDHL). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RDHL overvalued or undervalued right now?

At $0.66, 1 of 1 active models suggest RDHL may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits RedHill Biopharma Ltd.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 4.1 mean for RDHL?

RedHill Biopharma Ltd.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RDHL?

CirclFi analyzes RDHL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is RDHL a value trap in 2026?

RedHill Biopharma Ltd.'s Value Trap score is 50/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns RedHill Biopharma Ltd. (RDHL) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RDHL/ · Methodology
Primary sources for this RDHL valuation
  • Financial statements: RedHill Biopharma Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001553846) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RDHL as of ; valuations recomputed .